Palisade Bio Announced The Receipt Of The Second Milestone Payment To Giiant From The U.S. Crohn's And Colitis Foundation

-5.41%

Palisade Bio, Inc. - Common Stock

PALI

1.83

-5.41%

- Company's co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding as part of previously announced grant from the US Crohn's and Colitis Foundation

- Lead program, PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) advancing toward completion of IND-enabling studies with IND filing expected by Q3 2024

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.